Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS) Not Flying Under The Radar

Akums Drugs and Pharmaceuticals Limited's (NSE:AKUMS) price-to-earnings (or "P/E") ratio of 57.6x might make it look like a strong sell right now compared to the market in India, where around half of the companies have P/E ratios below 27x and even P/E's below 15x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/E.

We check all companies for important risks. See what we found for Akums Drugs and Pharmaceuticals in our free report.

Akums Drugs and Pharmaceuticals certainly has been doing a good job lately as it's been growing earnings more than most other companies. It seems that many are expecting the strong earnings performance to persist, which has raised the P/E. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

See our latest analysis for Akums Drugs and Pharmaceuticals

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Akums Drugs and Pharmaceuticals.

Is There Enough Growth For Akums Drugs and Pharmaceuticals?

There's an inherent assumption that a company should far outperform the market for P/E ratios like Akums Drugs and Pharmaceuticals' to be considered reasonable.

Taking a look back first, we see that the company grew earnings per share by an impressive 187% last year. Although, its longer-term performance hasn't been as strong with three-year EPS growth being relatively non-existent overall. So it appears to us that the company has had a mixed result in terms of growing earnings over that time.

Shifting to the future, estimates from the three analysts covering the company suggest earnings should grow by 114% over the next year. With the market only predicted to deliver 24%, the company is positioned for a stronger earnings result.

With this information, we can see why Akums Drugs and Pharmaceuticals is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.

What We Can Learn From Akums Drugs and Pharmaceuticals' P/E?

It's argued the price-to-earnings ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

As we suspected, our examination of Akums Drugs and Pharmaceuticals' analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. It's hard to see the share price falling strongly in the near future under these circumstances.

The company's balance sheet is another key area for risk analysis. You can assess many of the main risks through our free balance sheet analysis for Akums Drugs and Pharmaceuticals with six simple checks.

Of course, you might also be able to find a better stock than Akums Drugs and Pharmaceuticals. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.